We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Gilead Warned for Statements Minimizing Letairis Risk
Gilead Warned for Statements Minimizing Letairis Risk
March 13, 2009
A Gilead Sciences representative made false and misleading statements during a medical conference about the company’s pulmonary arterial hypertension (PAH) drug Letairis, minimizing its restricted distribution program and the risks of the product, an FDA untitled letter charges.